ライフサイエンスコーパス: benign lesion

1 as, eight metastases to the brain, and three benign lesions).

2 illary thyroid carcinomas clustered with the benign lesions).

3 (one of three high-risk lesions and 17 of 17 benign lesions).

4 lesions and with decreasing age at the first benign lesion.

5 atients had a malignant lesion, and 52 had a benign lesion.

6 diagnosed in 38 women (82.6%) while 8 had a benign lesion.

7 In most cases, it is a benign lesion.

8 33% (72 of 217) cancers and 67% (145 of 217) benign lesions.

9 ells at the onset of the disease, but not on benign lesions.

10 number of patients who will be found to have benign lesions.

11 tal pancreatectomy (MIDP) are equivalent for benign lesions.

12 etastatic PNETs and cervical carcinomas into benign lesions.

13 malignant lesions, as compared with ADCs of benign lesions.

14 rgical procedures performed in patients with benign lesions.

15 ologic analyses revealed 20 malignant and 72 benign lesions.

16 esions compared with adjacent histologically benign lesions.

17 d in malignant lesions compared with matched benign lesions.

18 T1 carcinomas, 24 T2-T4 carcinomas, and 114 benign lesions.

19 /- 0.03 for differentiation between DCIS and benign lesions.

20 ing early-stage invasive breast cancers from benign lesions.

21 IDC lesions associated with negative LNs and benign lesions.

22 ate a CNN model to distinguish malignant and benign lesions.

23 tes, approximately 5.6 million biopsies find benign lesions.

24 niques and encouraging outcomes for selected benign lesions.

25 ith the SM K(trans) value for each of the 15 benign lesions.

26 vessels and retinal cavernous hemangioma are benign lesions.

27 s many early breast cancers, yet detect many benign lesions.

28 II brain tumors; 2 had metastases; and 2 had benign lesions.

29 Results: There were 100 malignant and 41 benign lesions.

30 ve power (87%) in segregating malignant from benign lesions.

31 over long periods from specific preexisting benign lesions.

32 eriodic surveillance of a high proportion of benign lesions.

33 scores for uptake differences in most of the benign lesions.

34 ecause of their rarity and tendency to mimic benign lesions.

35 ntaining the carcinomas and 1 containing the benign lesions.

36 ignant, 8 pre-malignant, and the remaining 4 benign lesions.

37 ent schemes in a variety of almost certainly benign lesions.

38 in 25 lesions revealed 20 malignant and five benign lesions.

39 of spontaneous regression or maturation into benign lesions.

40 +/- 11.2 degrees between adipose tissue and benign lesions.

41 cell lines, but not normal mammary tissue or benign lesions.

42 discrimination between low-grade tumors and benign lesions.

43 ns: two of eight malignancies and two of two benign lesions.

44 maging follow-up was available for 92 of 119 benign lesions.

45 t previously published criteria for probably benign lesions.

46 20 malignant tumors, whereas 16 patients had benign lesions.

47 established diagnostic criteria for probably benign lesions.

48 o be useful in distinguishing malignant from benign lesions.

49 ain the ability of low-risk HPVs in inducing benign lesions.

50 anatomic abnormalities detected by CT to be benign lesions.

51 decrease the number of biopsies performed in benign lesions.

52 0 [69%] were invasive cancers) and 863 (66%) benign lesions.

53 to these simple cysts, and less surgery for benign lesions.

54 proven pancreatic adenocarcinoma and 13 had benign lesions.

55 There were 96 malignant and 170 benign lesions.

56 e 25 cancers, 38 fibroadenomas, and 23 other benign lesions.

57 6 HNSCC in contrast to its low expression in benign lesions.

58 c techniques to differentiate malignant from benign lesions.

59 d is particularly useful in the diagnosis of benign lesions.

60 s were indeterminate for a similar subset of benign lesions.

61 ecimens correspond to adenomas or even other benign lesions.

62 ask of differentiating between malignant and benign lesions.

63 There were 106 malignant and 76 benign lesions.

64 s found in 21 (88%) LM or LMM and in 3 (77%) benign lesions.

65 d 200 nonhematopoietic neoplasms, with 4,390 benign lesions.

66 malignant lesions are more frequent than the benign lesions.

67 on, removing the need for further imaging of benign lesions.

68 e T1, 19 were T2-T4 carcinomas, and 233 were benign lesions.

69 tinguishing malignant pigmented lesions from benign lesions.

70 task of distinguishing between malignant and benign lesions.

71 d after bronchoscopy in 35% of patients with benign lesions.

72 NR was 450% in malignant lesions, and 60% in benign lesions.

73 = .001, and P = .005, respectively) than in benign lesions.

74 l and increasingly used for removal of often benign lesions.

75 the 31 patients, 6 had malignant and 25 had benign lesions.

76 All OSSN signs were also observed in benign lesions.

77 malignant human prostate tissues compared to benign lesions.

78 n), 14 (15%) high-risk lesions, and 53 (55%) benign lesions.

79 ficantly more frequent in OSSN compared with benign lesions.

80 spontaneously grown malignant BC masses from benign lesions.

81 rue-positive (malignant) and false-positive (benign) lesions.

82 ificantly lower in malignant lesions than in benign lesions (0.17 vs. 0.70, P = 0.02).

83 deviation]), metastases (4.11 +/- 1.68), and benign lesions (0.59 +/- 0.31) were significant (P < .00

84 median index was 0.398 for non-proliferative benign lesions, 0.531 for proliferative benign lesions,

85 cent were for malignant tumors, 45% were for benign lesions, 1.7% were for live donor hepatectomies,

86 In 95 benign lesions, 13 (14%) had no SW elastography signal;

87 orrelates, and 53 (35%) of 152 patients with benign lesions, 15 (28%) with correlates (P < .0001).

88 ignificantly lower (P < .0001) than that for benign lesions (2.23 x 10(-3) mm(2)/sec +/- 0.87) at DW

89 ly higher in malignant (7.4 +/- 2.6) than in benign lesions (2.4 +/- 0.8) (P < 0.05).

90 x biopsy-proved cancers and 20 biopsy-proved benign lesions, 20 cases of probably benign findings in

91 Of the 310 benign lesions, 259 underwent mammographic follow-up at

92 s 11.2%, significantly higher than dogs with benign lesions (3.2%; p = 0.001).

93 with minimal increase in mean biopsy rate of benign lesions (43% [range, 26%-60%] before to 51% [rang

94 tically significant difference was found for benign lesions (44% vs 100%, P<.05).

95 lates, and in 140 (92%) of 152 patients with benign lesions, 51 (36%) with correlates (risk ratio, 1.

96 Twenty-six benign lesions (76%) and eight malignancies (24%) were d

97 BA administration: 25% of +/+ mice developed benign lesions; 88% of +/- showed multiple papillomas, a

98 Benign lesions accounted for 13% of indications, whereas

99 +/- 0.02 for differentiation between IDC and benign lesions and 0.79 +/- 0.03 for differentiation bet

100 IDC lesions associated with positive LNs and benign lesions and 0.83 +/- 0.03 for differentiation bet

101 The 109 renal lesions--81 benign lesions and 28 RCCs--had a mean diameter of 4.2 c

102 There were 21 benign lesions and 43 cancers (36 primary, seven metasta

103 ged retention of AMT, but 3 other lesions (2 benign lesions and a rectal cancer metastasis) and unaff

104 Nuclear Aurora-A was detected in benign lesions and became more diffused but broadly expr

105 Unusual lesions, such as malignant-looking benign lesions and benign-looking malignant lesions, wer

106 ressed in malignant disease as compared with benign lesions and could also define a subset of highly

107 IPLNs are benign lesions and do not require follow-up after initia

108 r each unknown case, eight similar images of benign lesions and eight similar images of malignant les

109 rotein in a fraction of the spinous cells in benign lesions and in cervical intraepithelial neoplasia

110 Angular separations of benign lesions and malignant lesions were significantly

111 M was unable to reliably distinguish between benign lesions and OSSN because of an overlap in their a

112 In addition to removing benign lesions and preventing progression to malignancy,

113 ADCs of benign lesions and RCCs were compared.

114 he optimal follow-up of cytologically proven benign lesions and sonographically nonsuspicious nodules

115 These models recapitulate early benign lesions and suggest that a latency period exists

116 uorine 18 fluorodeoxyglucose (FDG) uptake of benign lesions and that of malignant lesions.

117 ely selected the four most similar images of benign lesions and the four most similar images of malig

118 , in glandular tissue, between patients with benign lesions and those with malignant lesions (P =.04)

119 f the 100 patients did not have NSCLC (seven benign lesions and two metastatic tumors) and were exclu

120 tive benign lesions, 0.531 for proliferative benign lesions, and 0.644 for cancer (ductal carcinoma-i

121 test results, 910 biopsies or surgeries for benign lesions, and 190 overdiagnosed cases of cancer (3

122 psy-proven cancer, 35 cases of biopsy-proven benign lesions, and 52 normal or benign cases (Breast Im

123 ers classified the 130 cases (40 cancers, 24 benign lesions, and 66 normal images) using 2D mammograp

124 assessments, rate of biopsy of malignant and benign lesions, and areas under receiver operating chara

125 s are more common in malignant GISTs than in benign lesions, and it has been proposed that mutations

126 al intensity values among malignant lesions, benign lesions, and normal marrow, the differences in si

127 nography result, although 81.0% of them were benign lesions, and the other 19.0% needed follow-up or

128 tive lesions, 15 and 22 true-negative (i.e., benign) lesions, and eight and two false-negative lesion

129 or undetectable in normal mammary tissue and benign lesions, approximately two-thirds of breast tumou

130 Approximately 15-30 benign lesions are biopsied to diagnose each melanoma.

131 d 18q at or near the malignant transition of benign lesions as reported previously, irrespective of m

132 al studies report consistent loss of PAX2 in benign lesions as well as serous tumors.

133 llows their complete discrimination from the benign lesions, as validated by comparison with gold-sta

134 and neck, including preinvasive lesions and benign lesions associated with carcinogen exposure, were

135 in the task of differentiating malignant and benign lesions at mammography and sonography.

136 invasive carcinomas (malignant group) and 73 benign lesions (benign group).

137 melanomas biopsied and reduce the number of benign lesions biopsied, thereby improving patient outco

138 which knock-in of Braf(V600E) induces mostly benign lesions, Braf-expressing thyrocytes become transf

139 serrated polyps are a heterogeneous group of benign lesions, but some progress to colorectal cancer.

140 on in each patient (23 malignant lesions, 10 benign lesions) by two independent readers.

141 lated interstitial inflammation appear to be benign lesions, C4d deposition in association with inter

142 eoplasia comprise common well-differentiated benign lesions called leiomyomas (ULM), and rare, highly

143 High-grade gliomas, metastases, and benign lesions can be distinguished on the basis of meas

144 Benign lesions caused by loss of the neoplastic tumor su

145 Anogenital warts (AGWs) are considered benign lesions caused by low-risk HPV-types, whereas ano

146 us breast tissues (e.g. normal, malignant or benign lesions), cell lines and body fluids.

147 Benign lesions consisted of six adenomatoid tumors, two

148 ee percent of fibroadenomas and 56% of solid benign lesions could be distinguished from cancers by us

149 rgery, and 30.6% (91 of 297) of surgeries of benign lesions could have been avoided.

150 There were two groups of benign lesions: cysts (n = 31) and solid tumors (n = 12)

151 The malignant tumors and benign lesions demonstrated different Hb(T) and scatteri

152 e washout threshold of 50% on delayed scans; benign lesions demonstrated more than 50% washout; and m

153 Two benign lesions demonstrating less than 50% washout were

154 arise from polypoid adenomas, but how these benign lesions develop into malignant neoplasms is not u

155 arlier-stage malignancies, the percentage of benign lesions discovered has also increased.

156 lens and proper protection for patients with benign lesions during GKRS.

157 ly significant PCa (Gleason score >= 7), and benign lesions (eg, prostatitis); and justify classifica

158 ed 55.9 HU +/- 4.0 (standard error), whereas benign lesions enhanced 17.6 HU +/- 6.1 (P < .001).

159 80% (59 of 74) to 96% (71 of 74), monitoring benign lesions for change decreased from 43% (32 of 74)

160 The optimal ADC threshold to differentiate benign lesions from MPD with DW MR imaging was 1.52 x 10

161 CNBx potentially spares patients with benign lesions from unnecessary surgery, although false-

162 s (including all cancers) and in three of 26 benign lesions, giving MR spectroscopy a sensitivity of

163 all 12 (100%) cancers and three (15%) of 20 benign lesions, giving proton (1H) MR spectroscopy a sen

164 bin concentrations obtained in malignant and benign lesion groups, and P < .001 was considered to ind

165 Only two of 31 patients with benign lesions had an abnormal scan.

166 Benign lesions had SUVs of 1.14 +/- 0.64 (scan 1) and 1.

167 Unequivocally benign lesions harbored BRAF V600E mutations exclusively

168 njudiciously and unnecessarily excising many benign lesions has led to numerous techniques that assis

169 ally detected on chest radiographs, but many benign lesions have radiologic characteristics similar t

170 the number of surgical biopsies performed on benign lesions have the potential to improve patient car

171 ductal carcinoma in situ (DCIS) in six, and benign lesions in 34.

172 anoma skin cancer and frequent excisions for benign lesions in a relatively small number of patients

173 Cancer was missed in 8% (three of 40) of benign lesions in patients who were followed up.

174 t different types of lung cells can generate benign lesions in response to K-Ras oncogenic signals.

175 opathologic diagnoses were representative of benign lesions in seven cases, premalignant in 13, and m

176 Algorithm test performance for identifying benign lesions in the intervention cohort resulted in a

177 The 50 malignant and 48 benign lesions (in patients aged 19-83 years; mean age,

178 Other benign lesions included 11 with no detectable vessels, n

179 e tumors, and 39.3% (95% CI, 29.1%-50.3%) of benign lesions (including 11 of 12 inflammatory lesions)

180 proven pancreatic carcinoma, whereas 13 had benign lesions, including chronic pancreatitis (n = 10),

181 r all normal vertebrae (mean, 58.5%) and for benign lesions, including endplate degeneration (mean, 5

182 s (SUVs) less than 2.5 have been reported in benign lesions, including pneumonia.

183 In contrast, all benign lesions, including pyelonephritis, renal cysts, a

184 redisposes to the development of multifocal, benign lesions, including retinal and central nervous sy

185 In benign lesions induced by the small DNA tumor viruses, v

186 ectrum of these areas included unequivocally benign lesions, intermediate lesions, and intraepidermal

187 , three with other malignancies, and 27 with benign lesions involving gynecologic organs.

188 Malignant lesions had lower ADCs than benign lesions, irrespective of patient age (P < .02) an

189 ng features are discriminative for different benign lesions is influenced by cancer grade.

190 rall accuracy of biopsy for the diagnosis of benign lesions, many can be diagnosed with the aid of bi

191 cer cases and 51 controls with biopsy-proven benign lesions, matched by age and year-of-MRI.

192 n the evaluation of breast lesions, but some benign lesions may mimic malignant lesions; thus, this i

193 10 was, on average, 49% higher than that in benign lesions (mean size, 14 mm +/- 12; range, 6-35 mm)

194 differed significantly between patients with benign lesions (mean, 1.9) and patients with malignant l

195 ICCs), one neuroendocrine metastasis, and 27 benign lesions (median MR imaging follow-up, 95 months).

196 Papillary adenoma (PA) is a small benign lesion morphologically similar to PRCC and is sug

197 The benign lesions most frequently observed were ganglia, un

198 Of the 32 benign lesions, most (30 of 32) had activity less than t

199 Solid benign lesions (n = 17) and cysts (n = 8) had significan

200 aneurysmal bone cyst (ABC), and the related benign lesion nodular fasciitis.

201 virus (EBV) causes hairy leukoplakia (HL), a benign lesion of oral epithelium that occurs primarily i

202 ate SPECT for identifying both malignant and benign lesions of the skeleton.

203 Fifteen (18%) lesions were found to be benign lesions of unknown type at excision or mastectomy

204 y-six patients had unilocular cysts (35 with benign lesions, one with borderline neoplasm).

205 ncy, including malignant transformation of a benign lesion or development of radiation-associated sec

206 ients who were undergoing surgery for either benign lesions or localized lung cancer (control subject

207 ome is characterised by three main symptoms: benign lesions originating from hair follicles, variousl

208 Of the 213 patients, four had benign lesions other than hemangiomas.

209 ) showed significantly lower ADCs than other benign lesions (P < .0001) and were the most common lesi

210 ers had higher extraction-flow products than benign lesions (P < .001).

211 significant difference between malignant and benign lesions (P < .001).

212 lower levels of education than patients with benign lesions (P = .001).

213 atients with carcinoma than in patients with benign lesions (P = .002).

214 in 20 of 24 malignant lesions and in 2 of 5 benign lesions (P = 0.04).

215 um(2)/msec), and 0.65 (range, 0.44-1.43) for benign lesions (P values of .01, .02, < .001, respective

216 pposed to nonmass lesions) and malignant (vs benign) lesions (P < .001 for both).

217 cation was the nasal limbus (61% OSSN vs 78% benign lesions; P < .001).

218 Females predominated (67% of OSSN vs 64% of benign lesions; P = .65).

219 In the women with benign lesions, percentages of slope and enhancement for

220 present less frequently in malignant than in benign lesions (polygonal shape: 7% vs 38%, P = .02; smo

221 There were 29 malignant and 17 benign lesions (range, 6-95 mm; mean, 23.3 mm).

222 pecificity in differentiating malignant from benign lesions ranging from 73 to 98% and 71 to 100%, re

223 ivities previously observed in a spectrum of benign lesions regardless of HPV types present.

224 nant lesions showed a greater mean size than benign lesions regardless of the group (P = 0.015).

225 carcinomas, one follicular carcinoma and 22 benign lesions removed from children aged 5-19 were scre

226 Both benign lesions represented areas of fat necrosis.

227 lesions and 2.79+/-2.16 (range 0.6-8.7) for benign lesions, respectively (p<0.05).

228 LOH at 17p and 18q occurred in 0 and 16% of benign lesions, respectively, suggesting their role in m

229 rence to lexicon characteristics of probably benign lesions should improve specificity.

230 results from 14 patients (4 malignant and 10 benign lesions) show that there exist significant contra

231 The results for benign lesions showed an average density of 66.67 +/- 17

232 Benign lesions showed hypointense signal on T2W and DWI.

233 of approximately 100 um after 5 min, whereas benign lesions showed lower and more variable signals.

234 ectly upgraded the classification of only 20 benign lesions (specificity, 69%).

235 ed by a differential diagnosis that includes benign lesions such as focal inflammation, focal fibrosi

236 The SWV values of false positive benign lesions, such as: granulomatous mastitis, scleros

237 gen-presenting cells was limited compared to benign lesions, suggesting that primary and metastatic h

238 Eight (29.6%) of 27 patients with benign lesions tested positive for mutations, six (75%)

239 MRI depicted more nonindex suspicious benign lesions than did contrast-enhanced mammography or

240 th early disease (i.e., lower proportions in benign lesions than in more severe lesions), whereas sma

241 Verruciform xanthoma (VX) is a benign lesion that primarily affects the oral cavity, mo

242 regulated in PDAC compared to SMCA, the most benign lesion that rarely progresses to invasive carcino

243 develop a variety of focal hyperplastic and benign lesions that resemble lesions commonly found in h

244 Of the six benign lesions that were not surgically sampled for biop

245 For breast cancers versus benign lesions, the area under the symmetric summary rec

246 Among benign lesions, the model was used to correctly classify

247 Of the 32 benign lesions, there were 2 lesions with uptake equal t

248 task of discriminating between malignant and benign lesions to the prognostic tasks of distinguishing

249 in malignant lesions (11 of 17, 65%) than in benign lesions (two of 12, 17%; P = .02; PPV, 85%); mixe

250 in malignant lesions (11 of 27, 41%) than in benign lesions (two of 29, 7%; P = .004; PPV, 85%).

251 For diagnosis of malignant versus benign lesions, typical pairs of sensitivity and specifi

252 These benign lesions vary in their aggressiveness, clinical be

253 esions [P < .001]; eight of 42 patients with benign lesions vs 18 of 44 patients with malignant tumor

254 lesions [P = .178]; four of 42 patients with benign lesions vs 22 of 44 patients with malignant tumor

255 c lesions [P < .001]; 28 of 42 patients with benign lesions vs 42 of 44 patients with malignant tumor

256 llomaviruses (HPV) leads to the formation of benign lesions, warts, and in some cases, cervical cance

257 ancer according to age and the year when the benign lesion was identified.

258 The mean ADC value of benign lesions was 1.948+/-0.459x10(-3) mm(2)/s, while t

259 The median follow-up after biopsy of the benign lesions was 12 years.

260 Mean diameter of the benign lesions was 2.1 cm (range, 1.0-4.2 cm); mean diam

261 ), and K(app) to discriminate malignant from benign lesions was calculated, as was specificity at a s

262 tion to help differentiate malignancies from benign lesions was evaluated with a leave-one-out-by-cas

263 Pathologic analysis of benign lesions was performed on tissue obtained with ima

264 Follow-up in patients with 40 benign lesions was performed with repeat biopsy (n = 17,

265 mmographic follow-up (median, 24 months) for benign lesions was used to determine results.

266 Attenuation in six benign lesions was within 2 standard deviations of the m

267 sions, and the chemical-shift ratio in eight benign lesions was within 2 standard deviations of the m

268 d 10 with LCIS) adjacent to or in a targeted benign lesion were found.

269 The corresponding values of benign lesions were 54.1 mumol/L +/- 23.5, 38.0 mumol/L

270 s coefficient (K(app)) between malignant and benign lesions were assessed by using a logistic mixed m

271 of subjective image evaluation; four of five benign lesions were categorized correctly with both tech

272 (55.14%) lesions, and in 256 (43.17%) cases benign lesions were confirmed by histopathological exami

273 Two additional benign lesions were detected by each reader in session 2

274 In 83 subjects (70%), 103 benign lesions were detected.

275 The sensitivities for malignant and benign lesions were determined, with a comparison of the

276 f 37); in patients with previous malignancy, benign lesions were diagnosed in 18% (five of 27).

277 In patients without previous malignancy, benign lesions were diagnosed in 59% (22 of 37); in pati

278 In six cases, benign lesions were diagnosed on the basis of longitudin

279 Benign lesions were found at all sites in 10 patients (g

280 The locations of 22 benign lesions were measured over time to calibrate the

281 Frequency of clinical features in OSSN and benign lesions were recorded.

282 carcinomas (RCCs) and follow-up imaging for benign lesions were the reference standards.

283 The remaining 13 benign lesions were validated at excisional biopsy (n =

284 rrelates of MR imaging-detected malignant or benign lesions) were calculated as 30.7% (95% CI confide

285 one fulfilled strict criteria for a probably benign lesion when reviewed in retrospect.

286 easurement results indicated the lesion be a benign lesion, which is consistent with the tissue patho

287 18) and atypical (n = 2) lesions and for 11 benign lesions, which recurred or enlarged at follow-up.

288 We propose to classify these benign lesions, which share distinct histopathologic fea

289 on may help reduce the number of work-ups of benign lesions while maintaining high cancer detection r

290 Among 21 patients with benign lesions who underwent 6-month follow-up imaging,

291 gh ADC values, while meningioma was the only benign lesion with restricted diffusion.

292 d to define a substantial subset of probably benign lesions with a less than 2% chance of carcinoma a

293 sistance distinguished between malignant and benign lesions with an accuracy similar to that of open

294 th Vs of less than 4.5 m/sec were classified benign; lesions with Vs of 4.5 m/sec or greater, maligna

295 A total of 161 lesions (127 metastases, 34 benign lesions) with a mean size of 0.7 cm +/- 0.3 were

296 promising tool for differentiating MPD from benign lesions, with high accuracy, and supplementation

297 ibility and differentiation of malignant and benign lesions within the breast.Materials and Methods:

298 Mammographic follow-up was advised for the benign lesions without a repeat biopsy.

299 ional lesions detected in 3.5% (2 of 57) and benign lesion wrongly diagnosed on IOUS and CT as metast

300 7), 2) less metastases in 3.5% (2 of 57), 3) benign lesions wrongly diagnosed as metastasis on IOUS/C